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Abstract 
The emergence of COVID-19 outbreak caused by a novel coronavirus, was 
reported in Wuhan, Hubei, China in December 2019, and it spread rapidly 
across the world, resulting in the World Health Organization announcing a 
global health emergency on 30 January 2020. The first death caused by it in 
Iran was reported in February 2020 with aftermath outbreak across the country. 
The novel virus responsible for sever complications even death in all age 
groups, especially in older adults and people of any age who have serious 
underlying medical conditions. Researchers around the world are studying to 
identify the novel virus, SARS-CoV-2, with the aim of preventing its 
dissemination and to reduce its complications. Here, we discuss the available 
information regarding the SARS-CoV-2 Outbreak and disease caused as a 
mini-review. 
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Introduction 
The emergence of COVID-19 outbreak caused 
by a novel coronavirus, was reported in Wuhan, Hubei, 
China in December 2019, and it spread rapidly across 
the world, resulting in the World Health Organization 
(1) announcing a global health emergency on 30 
January 2020 (2). The first confirmed COVID-19 death 
in Iran was reported in February 2020 with a 
widespread outbreak during the next weeks across the 
country. Older adults and people of any age who have 
serious underlying medical conditions are at higher 
risk for developing severe complications from 
COVID-19 and even death (3). Researchers around the 
world are studying to identify the novel virus, Severe 
Acute Respiratory Syndrome coronavirus-2 (SARS-
CoV2), with the aim of preventing its dissemination 
and to reduce its complications. 
Origin of the coronaviruses  
Coronaviruses are single-stranded, positive-
sense RNA belonging to the family Coronaviridae. 
Coronaviridae along with Arteriviridae, Roniviridae 
and Mesoniviridae families, are in order Nidovirales; 
they all encode a set of subgenomic-nested mRNAs. 
Serologically, coronaviruses are divided into three 
serogroups, I and II (isolated from mammals) and 
serogroup III (isolated from birds). The prototype of 
group I is the human HcoV-229E virus; in addition, the 
group has the human HcoV-NL63 virus and several 
animal coronaviruses (4). The prototype of group II is 
murine hepatitis virus (MHV); this group also includes 
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human coronaviruses HcoV-OC43, HKU-1, SARS-
CoV and several other animal coronaviruses (4). 
The recent SARS-CoV2 (the cause of COVID-
19 disease) like SARS-CoV and MERS-CoV belongs 
to the zoonotic coronaviruses of the genus 
Betacoronavirus. The virus has a genome of about 30 
kb that encodes some structural and unstructured 
proteins (Figure 1) (5).  
Four major structural proteins include the Spike 
(S), the Envelope (E), the Membrane (M) and the 
Nucleocapsid (N) protein needed to produce a 
structurally complete viral particle (6, 7). Their virions 
have a round shape of 100-160 nm in diameter. They 
have distinct “spikes” or “peplomers” on the surface 
that give them a crownlike appearance (8). The 
genome forms a helical nucleocapsid in conjunction 
with phosphoprotein (9). There are two different types 
of spikes in the virion envelope: 
 S glycoproteins (formerly E2) found in all 
coronaviruses. S is a trimer and promote entry into 
cells. Neutralizing antibodies is also produced against 
S glycoprotein 
 Glycoprotein HE (formerly E1) or hemagglutinin 
esterase is present only in some group II coronaviruses, 
in short spike form and with disulfide bond dimers. 
This protein mutates over several passages and is 
eliminated. Therefore, HE is not required for virus 
replication. HE glycoprotein of coronavirus is about 
30% similar to the Influenza C Virus hemagglutinin. 
This glycoprotein is capable of binding to neuraminic 
acid and has acetyl esterase activity. Therefore. HE 
glycoprotein can facilitate virus release (9). 
S protein mediates the attachment and entering 
the host cell, so understanding its structure and 
function is important. The S Protein is a highly 
glycosylated type 1 transmembrane protein. 
Glycoprotein S is comprised of three domains, 
including the ectodomain, transmembrane domain, and 
endodomain. The ectodomain is divided into two 
subunits S1 and S2; the function of S1 is to bind the 
host cell receptors. The sequence of S1 amino acid is 
more variable than S2 (10). S protein has been 
identified as the major protein responsible for inducing 
the host immune response and developing neutralizing 
antibodies against the virus. Therefore, this protein 
could be an attractive target for immunotherapy against 
SARS-CoV2.  
 
Clinical feature of the virus 
Most coronaviruses naturally infect only one 
animal species or a few species close together. Before 
that, SARS-CoV was the only exception, because it can 
infect a wide range of mammals, including humans, 
primates, dogs, raccoons, cats, and rodents.  
In humans, coronaviruses generally causes mild 
respiratory infections such as those observed in the 
common cold; however, some coronavirus infections 
in humans have recently led to lethal endemics, which 
include the SARS (originated from Southern China), 
MERS (Middle East Respiratory Syndrome, Saudi 
Arabia in 2012) and COVID-19 (5). While no case of 
SARS-CoV infection has been reported since 2004, 
MERS-CoV has been around since 2012 and has 
caused multiple sporadic outbreaks in diff erent 
countries. 
Coronaviruses are the second leading cause of 
common colds after rhinoviruses. However, some 
recent human coronaviruses infections including 
MERS-CoV cause more severe complications such as 
middle east respiratory syndrome (12) and SARS-
CoV, the virus responsible for severe acute respiratory 
syndrome (13). Diarrhea is seen in patients with 
SARS-CoV infection; there is lymphopenia of TCD4 
and TCD8 cells in this disease. The virus can also cause 
liver disorders such as hepatitis. Patients of covid-19 
may experience flu like syndrome, fever, fatigue and 
Difficulty breathing (severe cases) (14, 15). 
Discusion 
Coronaviruses are often diagnosed in temperate 
climates between December and May and vary in 
 
Figure 1. Schematic structure of SARS-CoV2 (11). 
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frequency from year to year. Virus peak activity often 
occurs every two to four years. The virus is also present 
in nosocomial respiratory infections in intensive care 
units in children and in elderly care centers (16). There 
was no human circulation of the virus prior to the 
outbreak of SARS in 2002-2003. Although animals 
were the main source of the SARS-CoV and SARS-
CoV2, they have spread across the world from human 
to human (5). 
Unlike the usually mild disease associated with 
other human coronaviruses, SARS-CoV, MERS-CoV 
and SARS-CoV2 viruses usually results in severe 
lower respiratory disease requiring hospitalization. 
Although SARS-CoV and SARS-CoV2 belong to the 
beta-coronavirus subgroup, their genome-level 
similarity is only 70%, and the novel virus shows 
significant genetic differences with agent of SARS (5). 
WHO (World Health Organization), in its first 
emergency meeting estimated that the crude mortality 
ratio (the number of deaths reported by cases) of 
COVID-19 is around 4%. The virus infects people of 
all ages (17).  
Various reports related to SARS-CoV suggest a 
protective role of both humoral and cell-mediated 
immune responses. One of overexpress protein in the 
virus is N protein. The protein has well 
immunogenicity and is one of the vaccine candidate 
(18). Different study have shown there are acceptable 
cell mediate immunity (CTL) against S and N proteins. 
(19). Another study showed there was similarity in 
antigenic epitopes for T and B cells between SARS-
CoV and SARS-CoV2A (5).  
Many efforts are being made to develop an 
effective covid-19 vaccine based on Replicating Viral 
Vector, Non Replicating Viral Vector, RNA, DNA, 
Inactivated and Live Attenuated Virus, and Protein 
Subunit platform, all of which are in the pre-clinical 
evaluation phase (20). However, there are not any 
approved antiviral drugs or vaccines to protect against 
COVID-19 disease yet for use in the human host. 
Considering the prevalence of this disease and its 
worldwide mortality, the design and development of an 
effective vaccine against the disease seems urgent. 
Currently, the most effective way to protect 
against the novel coronavirus is by maintaining 
personal hygiene and the implementation of quarantine 
measures based on WHO recommendations 
Conclusion    
As highlighted Coronaviridae family conclude 
some viruses can cause lethal epidemic and pandemic 
in recent decade. Furthermore, scientist should change 
their revision about this family and study more about 
virology and pathogenesis of the viruses to create 
efficient vaccines and therapies. 
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